Covidien European launch for brain aneurysm device; Consano Medical gets Series A;

@FierceMedDev: Check out our newest special report: Top 10 med tech R&D budgets. Read | Follow @FierceMedDev

@StacyALawrence: Newly public Inogen gains on FDA clearance for home oxygen device. Story | Follow @StacyALawrence

@MichaelGFierce: Intersect ENT files for $80M IPO to support steroid-delivering sinus implants. More via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Ultrasound therapy outfit rakes in $2M for wearable chronic pain device. Story | Follow @EmilyWFierce

> Europe will see the release of a new device from Covidien ($COV), Pipeline Flex embolization, for unruptured brain aneurysms. The new technology is designed for easy deployment without unnecessarily taking up space. Story

> Consano Medical, a medical device company that split off from medical device incubator TheraNova, closed a Series A funding round at $3.9 million, thanks to the targeted investor technology of Deals Lab, an online financing platform. Release

> FDA has issued a Global Unique Device Identification Database (GUDID) guidance to explain how the database is to be used in connection with the Unique Device Identification (UDI) system. Full guidance

Biotech News

@FierceBiotech: Polaris preps for a $400M fund to back a new wave of biotechs. More | Follow @FierceBiotech

@JohnCFierce: Biotech vets target $43M round to debut new antifungal venture. Story | Follow @JohnCFierce

@DamianFierce: We need to commission an inversion graphic for future stories. Article | Follow @DamianFierce

@EmilyMFierce: Gives a new meaning to YOLO: The Higgs Boson should have crushed the universe. More | Follow @EmilyMFierce

> Boehringer bags a 'breakthrough' tag for its Pradaxa antidote. Story

> Auxilium eyes a Canadian biotech for a tax-cutting merger. More

> FDA experts spurn AstraZeneca's pitch for ovarian cancer drug olaparib. Article

Pharma News

@FiercePharma: Special: The top 5 vaccines by 2020. Report | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: Actavis says growing production at plant in Malta called for new warehouse. More | Follow @EricPFierce

@CarlyHFierce: Here's this week's issue of FierceVaccines. Hint: It's a good one. Issue | Follow @CarlyHFierce

> Eli Lilly's anti-takeover superpower? A shield forged by Indiana lawmakers. Story

> Biogen MS blockbuster Tecfidera earns high marks for safety. Article

> Reuters: Valeant supporter Paulson grabs 6 million-plus Allergan shares. More

> After 4-year Benicar review, FDA slaps aside heart-risk worries. News

Vaccines News

> Italian officials probe Novartis for possible flu vaccine pricing fraud. Story

> FDA slaps Glaxo with warning letter for FluLaval plant. More

> CDC committee recommends AZ's FluMist over flu shot in children. Article

> The top 5 vaccines by 2020. Report

> Feds charge researcher in HIV vaccine fraud case. More

> Reuters: Sanofi plans to put dengue program into separate unit. News

Pharma Manufacturing News

> FDA finds contamination issues at GSK vax plant. More

> India production expert urges excellence from drugmakers. Story

> New Indian government looks to help small players finance upgrades. Article

> Sanofi buys Dubai's Globalpharma to produce generics in the Middle East. News

> Actavis opens $18M warehouse on Malta. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.